ClinicalTrials.gg
CompletedNCT02363348Updated Mar 4, 2016

Efficacy and Safety of L Arginine to Prevent Preeclampsia

A Phase 3 interventional study of L arginine and Placebo in Preeclampsia, sponsored by Hospital Civil Juan I. Menchaca. Completed at 1 site in Mexico. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2016-03-04.

Sponsored by Hospital Civil Juan I. Menchaca · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Pre-Eclampsia with a site in Mexico — 2 open to participants now, 2 under way, none of them phase 3. Pre-Eclampsia · Mexico.

Started
2010
with 1 other
Phase 3
Only one
of the 11
Registered
3rd of 11
by date
Lead sponsor
1 of 11
Hospital Civil Juan I. Menchaca

Among the 11 studies in Pre-Eclampsia with a site in Mexico, this one is one of 2 that started in 2010, is the only one in phase 3, and was the 3rd registered.

Pre-Eclampsia

918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.

Browse Pre-Eclampsia studies →

Open to participants now

2 of the 11 studies in Pre-Eclampsia with a site in Mexico are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.

This study: 18 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pre-Eclampsia with a site in Mexico, or all of them as a file.
02

Study summary

Randomized double-blind controled clinical trial to assess the efficacy and safety of L-arginine to prevent preeclampsia.

applied to pregnant women with risk factors for preeclampsia. the main result was the development of preeclampsia as well as side effects to taking l arginine besides perinatal outcomes

Read the detailed description

Two groups were formed. one received L arginine 3 grams orally at day from the 20th week of pregnancy. the other group received placebo.

Each three weeks were evaluated in search of high blood pressure and proteinuria.

The follow-up was until the end of pregnancy and two weeks after this

03

Conditions studied

  • Preeclampsia

Browse trials for

Keywords

  • L arginine
  • Preeclampsia
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • one or more risk factors for developing preeclampsia (nulliparous, previous history of preeclampsia, chronic hypertension, ≥30)

Exclusion criteria

Exclusion Criteria:

  • pregnant women carriers of chronic renal failure
  • pre gestational diabetes
  • multiple pregnancy and were removed for some reason they received medication that would interfere with the interpretation of results (aspirin)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
96 participants (actual)

Study arms

  • Placebo comparator
    Placebo (A)

    were administered 5 capsules per day each capsule contained 600 mg of magnesia calcinada. Duration: from week 20th of pregnancy until the end of the same. dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.

    Other: Placebo

  • Experimental
    L arginine (B)

    were administered 5 capsules per day each capsule contained 600 mg of L arginine. Duration: from week 20th of pregnancy until the end of the same dose was administered as follows: two capsules in the morning at breakfast and three capsules at night in dinner.

    Dietary Supplement: L arginine

Interventions

  • Dietary supplementArginineStudies of ArginineArginine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.

  • OtherPlacebo

    calcined magnesia

06

What researchers measure

Primary outcomes

  1. efficacy of L arginine to prevent preeclampsia

    number of patients with diagnosis of preeclampsia. the diagnostic was performed when they presented arterial blood pressure above 140/90 mm / Hg in the span of 6 hours and accompanied by proteinuria (\>300 milligrams in one sample) number of patients with high blood pression and proteinuria (ACOG criteria) The evaluations were performed every three weeks until week 31, then every two weeks until week 35 and weekly until pregnancy ended

    Time frame: from time of randomization until the date of diagnostic of preeclampsia or two weeks after delivery wichever came first. approximalety 20 weeks.

Secondary outcomes

  1. perinatal outcome

    number of patients with adverse perinatal outcome: APGAR scale \< 7 at five minutes, low weight for gestational age (\< 10 percentile) and CAPURRO scale \< 37 weeks also the need to enter the neonatal intensive care unit

    Time frame: from time to delivery until two weeks after, approximalety 18 weeks

  2. safety of L arginine

    number of patients with adverse reactions and/or any alteration of blood test. participants are awarded a diary which recorded the symptoms that caused them any discomfort. If the discomfort was important it was reported via telephone with the treating physician. the paper was reviewed at each appointment. Blood tests such as blood count, liver function tests and kidney were performed every three weeks in search of alterations in the parameters considered normal by those tests (ACOG criteria)

    Time frame: from time of randomization until birth approximalety 18 weeks

07

Study locations

1 site
  • Panduro Baron J Guadalupe
    Guadalajara, Jalisco 44340, Mexico
08

References and documents

Publications

  • Johal T, Lees CC, Everett TR, Wilkinson IB. The nitric oxide pathway and possible therapeutic options in pre-eclampsia. Br J Clin Pharmacol. 2014 Aug;78(2):244-57. doi: 10.1111/bcp.12301. PubMed 24313856 ↗
  • Vadillo-Ortega F, Perichart-Perera O, Espino S, Avila-Vergara MA, Ibarra I, Ahued R, Godines M, Parry S, Macones G, Strauss JF. Effect of supplementation during pregnancy with L-arginine and antioxidant vitamins in medical food on pre-eclampsia in high risk population: randomised controlled trial. BMJ. 2011 May 19;342:d2901. doi: 10.1136/bmj.d2901. PubMed 21596735 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Aug 2013 and a completion of Mar 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2015
First posted
Feb 16, 2015
Start
Aug 2010
Primary completionActual
Aug 2013
CompletionActual
Mar 2014
Last update
Mar 4, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02363348
Lead sponsor
Hospital Civil Juan I. Menchaca
Responsible party
Eva Elizabet Camarena Pulido (MD, Hospital Civil Juan I. Menchaca) — Principal investigator
First posted
Feb 16, 2015
Start date
Aug 2010
Primary completion
Aug 2013
Completion
Mar 2014
Last update
Mar 4, 2016

Study contacts

Guadalupe Panduro, Ph
study chair · Hospital Civil Juan I. Menchaca

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arginine

Start the discussion